Genexine announced that late-breaking results from the Phase 2 clinical trial study of its therapeutic DNA vaccine GX-188E in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), were selected for an oral presentation at the 2022 European Society for Medical Oncology Congress which is being held from September 9-13 in Paris, France.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7,240 KRW | -2.56% | -3.60% | -26.87% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.87% | 226M | |
+2.91% | 108B | |
+10.33% | 105B | |
+1.57% | 23.46B | |
-12.34% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.81% | 17.19B | |
+6.39% | 13.99B | |
+37.05% | 12.53B |
- Stock Market
- Equities
- A095700 Stock
- News Genexine, Inc.
- Genexine to Present Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology Congress 2022